{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:23:26Z","timestamp":1761823406208},"reference-count":28,"publisher":"EDP Sciences","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Sci (Paris)"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1051\/medsci\/20082411967","type":"journal-article","created":{"date-parts":[[2011,3,5]],"date-time":"2011-03-05T06:28:55Z","timestamp":1299306535000},"page":"967-971","source":"Crossref","is-referenced-by-count":4,"title":["De nouvelles perspectives th\u00e9rapeutiques pour l\u2019arsenic"],"prefix":"10.1051","volume":"24","author":[{"given":"Pierre","family":"Bob\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mounira K.","family":"Chelbi-Alix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2008,11,15]]},"reference":[{"key":"R1","unstructured":"Chen GQ, Shi XG, Tang W,et al.Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL). I. As2O3exerts dose-dependent dual effects on APL cells.Blood1997; 89 : 3345\u201353."},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Dilda PJ, Hogg PJ. Arsenical-based cancer drugs.Cancer Treat Rev2007; 33 : 542\u201364.","DOI":"10.1016\/j.ctrv.2007.05.001"},{"key":"R3","unstructured":"Alibert JL. Nouveaux \u00e9l\u00e9ments de th\u00e9rapeutique et de mati\u00e8re m\u00e9dicale, suivis d\u2019un nouvel essai sur l\u2019art de formuler.Paris, Chez Crapart, Caille et Ravier, 2 vol1804."},{"key":"R4","unstructured":"Lissauer H. Zwei Faelle von Leucaemie.Berl Klin Wochenschr1865; 2 : 403\u20135."},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Forkner C, McNair-Scott T. Arsenic as a therapeutic agent in chronic myeloid leukemia.JAMA1931; 97 : 305.","DOI":"10.1001\/jama.1931.02730010007002"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Lallemand-Breitenbach V, Zhu J, de Th\u00e9 H. La leuc\u00e9mie aigu\u00eb promy\u00e9locytaire : un paradigme cibl\u00e9s sur l\u2019oncog\u00e8ne ?Med Sci (Paris)2001; 17: 14\u201322.","DOI":"10.4267\/10608\/1783"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Grignani F, Valtieri M, Gabbianelli M,et al.PML\/RARa fusion protein expression in normal human hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype.Blood2000; 96 : 1531\u20137.","DOI":"10.1182\/blood.V96.4.1531"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"De Th\u00e9 H, Chelbi-Alix MK. APL, a model disease for cancer therapies ?Oncogene2001; 20 : 7136\u20139.","DOI":"10.1038\/sj.onc.1204851"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"Huang ME, Ye YC, Chen SR,et al.Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.Blood1988; 72 : 567\u201372.","DOI":"10.1182\/blood.V72.2.567.bloodjournal722567"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Soignet SL, Maslak P, Wang ZG,et al.Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.N Engl J Med1998; 339 : 1341\u20138.","DOI":"10.1056\/NEJM199811053391901"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Brown D, Kogan S, Lagasse E,et al.A PMLRARalpha transgene initiates murine acute promyelocytic leukemia.Proc Natl Acad Sci USA1997; 94 : 2551\u20136.","DOI":"10.1073\/pnas.94.6.2551"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Zhu J, Koken MH, Quignon F,et al.Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia.Proc Natl Acad Sci USA1997; 94 : 3978\u201383.","DOI":"10.1073\/pnas.94.8.3978"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Zhu J, Gianni M, Kopf E,et al.Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor a (RARa) and oncogenic RARa fusion proteins.Proc Natl Acad Sci USA1999; 96 : 14807\u201312.","DOI":"10.1073\/pnas.96.26.14807"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Zhang TD, Chen GQ, Wang ZG,et al.Arsenic trioxide, a therapeutic agent for APL.Oncogene2001; 20 : 7146\u201353.","DOI":"10.1038\/sj.onc.1204762"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Rieux-Laucat F, Le Deist F, Hivroz C,et al.Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity.Science1995; 268 : 1347\u20139.","DOI":"10.1126\/science.7539157"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Bid\u00e8re N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system.Annu Rev Immunol2006; 24 : 321\u201352.","DOI":"10.1146\/annurev.immunol.24.021605.090513"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Rieux-Laucat F. Le syndrome lymphoprolif\u00e9ratif avec auto-immunit\u00e9 : un d\u00e9faut h\u00e9rit\u00e9 ou acquis d\u2019apoptose lymphocytaire.Med Sci (Paris)2006; 22 : 645\u201350.","DOI":"10.1051\/medsci\/20062267645"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Renno T, Attinger A, Rimoldi D,et al.Expression of B220 on activated T cell blasts precedes apoptosis.Eur J Immunol1998; 28 : 540\u20137.","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<540::AID-IMMU540>3.3.CO;2-P"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Benihoud K, Bonardelle D, Bob\u00e9 P,et al.MRL\/lprCD4-CD8-and CD8+T cells, respectively, mediate Fas-dependent and perforin cytotoxic pathways.Eur J Immunol1997; 27 : 415\u201320.","DOI":"10.1002\/eji.1830270211"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Bob\u00e9 P, Bonardelle D, Reyn\u00e8s M,et al.Fas-mediated liver damage in MRL hemopoietic chimeras undergoinglpr-mediated graft-versus-host disease.J Immunol1997; 159 : 4197\u2013204.","DOI":"10.4049\/jimmunol.159.9.4197"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Bonardelle D, Benihoud K, Kiger N,et al.B lymphocytes mediate Fas-dependent cytotoxicity in MRL\/lprmice.J Leukoc Biol2005; 78 : 1052\u20139.","DOI":"10.1189\/jlb.0904536"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Adachi M, Suematsu S, Kondo T,et al.Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver.Nat Genet1995; 11 : 294\u2013300.","DOI":"10.1038\/ng1195-294"},{"key":"R23","unstructured":"Bonardelle D, Bob\u00e9 P, Reyn\u00e8s M,et al.Inflammatory arthropathy in MRL hematopoietic chimeras undergoing Fas mediated graft-versus-host syndrome.J Rheumatol2001; 28 : 956\u201361."},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Bob\u00e9 P, Bonardelle D, Benihoud K,et al.Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL\/lpr mice.Blood2006; 108 : 3967\u201375.","DOI":"10.1182\/blood-2006-04-020610"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Feldmann M, Maini RN. Anti-TNF-a therapy of rheumatoid arthritis: what have we learned ?Annu Rev Immunol2001; 19 : 163\u201396.","DOI":"10.1146\/annurev.immunol.19.1.163"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Durelli L, Ricci A. Anti-interferon antibodies in multiple sclerosis. Molecular basis and their impact on clinical efficacy.Front Biosci2004; 9 : 2192\u2013204.","DOI":"10.2741\/1329"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Parisotto M, Brodeur H, Bhat PV, Mader S. M\u00e9tabolisme des r\u00e9tino\u00efdes et cancer.Med Sci (Paris)2006; 22 : 1101\u20136.","DOI":"10.1051\/medsci\/200622121101"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Bensussan A, Bizzini B, Pouletty P, Gallo RC, Zagury D. Les kino\u00efdes : Une nouvelle g\u00e9n\u00e9ration de vaccins th\u00e9rapeutiques.Med Sci (Paris)2008; 24 : 306\u201313.","DOI":"10.1051\/medsci\/2008243306"}],"container-title":["m\u00e9decine\/sciences"],"original-title":[],"link":[{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/20082411967\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T14:13:17Z","timestamp":1685974397000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.medecinesciences.org\/10.1051\/medsci\/20082411967"}},"subtitle":["De la leuc\u00e9mie aigu\u00eb promy\u00e9locytaire aux maladies auto-immunes"],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":28,"journal-issue":{"issue":"11"},"alternative-id":["medsci20082411p967"],"URL":"https:\/\/doi.org\/10.1051\/medsci\/20082411967","relation":{},"ISSN":["0767-0974","1958-5381"],"issn-type":[{"value":"0767-0974","type":"print"},{"value":"1958-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}